RxDoctor Payments Data

Sarah Lear

Nurse Practitioner · Round Rock, TXNPI 1902516537

Payments from drug & device makers

$3,118in general payments, 2019–2025

Across 173 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bristol Myers Squibb$415
  • Pfizer$345
  • Johnson & Johnson$278
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$163
  • QOL Medical, LLC$106
  • plus $614 from 16 others

What the payments were for

  • Food & beverage$3,08299%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,118 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$18,385
Medicare patients
160
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin13$35,952
ClenpiqSod Picosulf/Mag Ox/Citric Ac29$4,964
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C21$2,945
Mesalamine22$2,745
Dicyclomine Hcl13$501
Esomeprazole Magnesium16$429
Sucralfate11$416
Pantoprazole Sodium66$389
Omeprazole53$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$163$38,89834 claims
Ferring Pharmaceuticals Inc.Clenpiq$19$4,96429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →